Sign In To Continue
You have reached the guest article limit.
Unlock more of the IIPLA newsroom by signing in with SSO or joining as a member.
Lupin Ltd., a leading Indian pharmaceutical firm, has reached a $90 million settlement with Japan-based Astellas Pharma Inc. to resolve ongoing patent disputes concerning the U.S. rights to mirabegron, a drug used to treat overactive bladder. The agreement allows Lupin to continue marketing its generic version in the…
Share This Article
Ready-to-post copy includes the article link.
Lupin Resolves U.S. Patent Litigation with Astellas Pharma Through $90 Million Settlement Lupin Ltd., a leading Indian pharmaceutical firm, has reached a $90 million settlement with Japan-based Astellas Pharma Inc. to resolve ongoing patent disputes concerning the U.S. rights to mirabegron, a drug used to tr... Read the full IIPLA article: https://iipla.org/news/lupin-resolves-u-s-patent-litigation-with-astellas-pharma-through-90-million-settlement